InBioGen Co Ltd (101140) — Cash Flow-to-Debt Ratio
InBioGen Co Ltd (101140) has a Cash Flow-to-Debt Ratio of -0.68x as of September 2025, meaning its operating cash flow of ₩-1.67 Billion could theoretically repay -1% of its total liabilities (₩2.44 Billion) in one year. See InBioGen Co Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
InBioGen Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for InBioGen Co Ltd across 12 annual periods. Also explore InBioGen Co Ltd (101140) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for InBioGen Co Ltd (2013–2024)
Year-by-year debt coverage analysis for InBioGen Co Ltd. For market capitalisation and broader financial context, see InBioGen Co Ltd stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.01x | ₩-33.13 Million | ₩2.89 Billion | ▲ +97.1% |
| 2023 | -0.40x | ₩-1.05 Billion | ₩2.62 Billion | ▼ -30.3% |
| 2022 | -0.31x | ₩-11.51 Billion | ₩37.40 Billion | ▼ -319.7% |
| 2021 | -0.07x | ₩-7.07 Billion | ₩96.45 Billion | ▲ +82.7% |
| 2020 | -0.42x | ₩-8.03 Billion | ₩18.97 Billion | ▼ -175.6% |
| 2019 | -0.15x | ₩-3.83 Billion | ₩24.92 Billion | ▲ +91.2% |
| 2018 | -1.75x | ₩-1.70 Billion | ₩968.80 Million | ▼ -749.2% |
| 2017 | -0.21x | ₩-426.44 Million | ₩2.07 Billion | ▼ -496.8% |
| 2016 | 0.05x | ₩344.75 Million | ₩6.62 Billion | ▲ +103.2% |
| 2015 | -1.62x | ₩-10.96 Billion | ₩6.76 Billion | ▼ -595.5% |
| 2014 | -0.23x | ₩-695.95 Million | ₩2.99 Billion | ▼ -30.4% |
| 2013 | -0.18x | ₩-1.13 Billion | ₩6.33 Billion | — |